Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

42.57 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,908
Open 42.57
Bid (Size) 42.59 (6)
Ask (Size) 42.63 (9)
Prev. Close 42.57
Today's Range 42.57 - 42.57
52wk Range 33.67 - 43.84
Shares Outstanding 5,385,189,617
Dividend Yield 3.39%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout?
Moderna is forming its first base in over a year. Could shares top a buy point on the company's sales beat? 
Via Investor's Business Daily
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
While these sleeper stocks to buy don’t attract the spotlight, the lack of attention makes these ideas even more enticing. 
Via InvestorPlace

Performance

YTD
+13.49%
+13.49%
1 Month
+0.35%
+0.35%
3 Month
+7.94%
+7.94%
6 Month
+23.11%
+23.11%
1 Year
+17.11%
+17.11%

More News

Read More
GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Via Benzinga
Forget the Fed. These 3 Stocks Will Soar No Matter What
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Peering Into GSK's Recent Short Interest
Via Benzinga
Wall Street Set To Open Lower After AMD Earnings Disappoint As Traders Look To Fed's Powell For Relief: Why This Analyst Sees Incoming Summer Rally
Via Benzinga
Topics Economy
Exposures Interest Rates
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
What's Going On With Pfizer Stock On Thursday?
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Via Benzinga
Topics Brexit
Exposures Brexit
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
Via Benzinga
GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years
Via Benzinga
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Down 75%. Is Agenus Stock a Buy on the Dip?
Via The Motley Fool
CureVac, GS Partner Release Data On Influenza Vaccine Study
Via Benzinga
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Via MarketBeat
Exposures Product Safety
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
Via The Motley Fool
Russell 2000 Index Best And Worst Performing Stocks Of 2024
Via Talk Markets
Topics Stocks
Exposures US Equities
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
Via The Motley Fool
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
Via Benzinga
GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer
Via Benzinga
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.